Logo image of ADPT

ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Fundamental Analysis

NASDAQ:ADPT - US00650F1093 - Common Stock

12.8 USD
+0.13 (+1.03%)
Last: 8/26/2025, 4:30:00 PM
12.7998 USD
0 (0%)
After Hours: 8/26/2025, 4:30:00 PM
Fundamental Rating

3

Overall ADPT gets a fundamental rating of 3 out of 10. We evaluated ADPT against 54 industry peers in the Life Sciences Tools & Services industry. ADPT may be in some trouble as it scores bad on both profitability and health. ADPT shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADPT has reported negative net income.
ADPT had a negative operating cash flow in the past year.
ADPT had negative earnings in each of the past 5 years.
In the past 5 years ADPT always reported negative operating cash flow.
ADPT Yearly Net Income VS EBIT VS OCF VS FCFADPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

The Return On Assets of ADPT (-24.41%) is worse than 72.22% of its industry peers.
ADPT's Return On Equity of -67.46% is on the low side compared to the rest of the industry. ADPT is outperformed by 74.07% of its industry peers.
Industry RankSector Rank
ROA -24.41%
ROE -67.46%
ROIC N/A
ROA(3y)-29%
ROA(5y)-24.51%
ROE(3y)-64.95%
ROE(5y)-49.77%
ROIC(3y)N/A
ROIC(5y)N/A
ADPT Yearly ROA, ROE, ROICADPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Gross Margin of ADPT (66.04%) is better than 88.89% of its industry peers.
In the last couple of years the Gross Margin of ADPT has declined.
The Profit Margin and Operating Margin are not available for ADPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
ADPT Yearly Profit, Operating, Gross MarginsADPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADPT has more shares outstanding
The number of shares outstanding for ADPT has been increased compared to 5 years ago.
ADPT has a worse debt/assets ratio than last year.
ADPT Yearly Shares OutstandingADPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
ADPT Yearly Total Debt VS Total AssetsADPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.16, we must say that ADPT is in the distress zone and has some risk of bankruptcy.
ADPT has a worse Altman-Z score (-0.16) than 77.78% of its industry peers.
A Debt/Equity ratio of 0.73 indicates that ADPT is somewhat dependend on debt financing.
ADPT has a Debt to Equity ratio of 0.73. This is in the lower half of the industry: ADPT underperforms 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Altman-Z -0.16
ROIC/WACCN/A
WACC10.57%
ADPT Yearly LT Debt VS Equity VS FCFADPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

ADPT has a Current Ratio of 2.84. This indicates that ADPT is financially healthy and has no problem in meeting its short term obligations.
ADPT has a Current ratio of 2.84. This is comparable to the rest of the industry: ADPT outperforms 55.56% of its industry peers.
A Quick Ratio of 2.75 indicates that ADPT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.75, ADPT is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.84
Quick Ratio 2.75
ADPT Yearly Current Assets VS Current LiabilitesADPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

ADPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.43%, which is quite impressive.
The Revenue has grown by 21.60% in the past year. This is a very strong growth!
Measured over the past years, ADPT shows a quite strong growth in Revenue. The Revenue has been growing by 16.03% on average per year.
EPS 1Y (TTM)36.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.16%
Revenue 1Y (TTM)21.6%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%36.33%

3.2 Future

ADPT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.82% yearly.
ADPT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.29% yearly.
EPS Next Y32.09%
EPS Next 2Y20.27%
EPS Next 3Y18.97%
EPS Next 5Y20.82%
Revenue Next Year31.1%
Revenue Next 2Y23.22%
Revenue Next 3Y23.55%
Revenue Next 5Y20.29%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADPT Yearly Revenue VS EstimatesADPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
ADPT Yearly EPS VS EstimatesADPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADPT. In the last year negative earnings were reported.
Also next year ADPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADPT Price Earnings VS Forward Price EarningsADPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADPT Per share dataADPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ADPT's earnings are expected to grow with 18.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.27%
EPS Next 3Y18.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIVE BIOTECHNOLOGIES

NASDAQ:ADPT (8/26/2025, 4:30:00 PM)

After market: 12.7998 0 (0%)

12.8

+0.13 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners94.38%
Inst Owner Change-3.45%
Ins Owners2.62%
Ins Owner Change0.03%
Market Cap1.95B
Analysts82.86
Price Target14.28 (11.56%)
Short Float %6.76%
Short Ratio4.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.58%
Min EPS beat(2)30.19%
Max EPS beat(2)32.96%
EPS beat(4)4
Avg EPS beat(4)25.03%
Min EPS beat(4)12%
Max EPS beat(4)32.96%
EPS beat(8)7
Avg EPS beat(8)15.53%
EPS beat(12)10
Avg EPS beat(12)13.68%
EPS beat(16)14
Avg EPS beat(16)12.45%
Revenue beat(2)2
Avg Revenue beat(2)18.66%
Min Revenue beat(2)16.85%
Max Revenue beat(2)20.47%
Revenue beat(4)4
Avg Revenue beat(4)12.9%
Min Revenue beat(4)1.07%
Max Revenue beat(4)20.47%
Revenue beat(8)6
Avg Revenue beat(8)5.77%
Revenue beat(12)8
Avg Revenue beat(12)4.15%
Revenue beat(16)12
Avg Revenue beat(16)3.67%
PT rev (1m)15.07%
PT rev (3m)23.53%
EPS NQ rev (1m)12.76%
EPS NQ rev (3m)11.72%
EPS NY rev (1m)14.5%
EPS NY rev (3m)13.22%
Revenue NQ rev (1m)6.79%
Revenue NQ rev (3m)3.42%
Revenue NY rev (1m)6.73%
Revenue NY rev (3m)6.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.5
P/FCF N/A
P/OCF N/A
P/B 10.85
P/tB 33.51
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS1.35
BVpS1.18
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.41%
ROE -67.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.04%
FCFM N/A
ROA(3y)-29%
ROA(5y)-24.51%
ROE(3y)-64.95%
ROE(5y)-49.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.8%
Cap/Sales 1.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.84
Quick Ratio 2.75
Altman-Z -0.16
F-Score4
WACC10.57%
ROIC/WACCN/A
Cap/Depr(3y)48.38%
Cap/Depr(5y)161.41%
Cap/Sales(3y)5.71%
Cap/Sales(5y)15.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.16%
EPS Next Y32.09%
EPS Next 2Y20.27%
EPS Next 3Y18.97%
EPS Next 5Y20.82%
Revenue 1Y (TTM)21.6%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%36.33%
Revenue Next Year31.1%
Revenue Next 2Y23.22%
Revenue Next 3Y23.55%
Revenue Next 5Y20.29%
EBIT growth 1Y34.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.32%
EBIT Next 3Y27.22%
EBIT Next 5Y27.77%
FCF growth 1Y51.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.12%
OCF growth 3YN/A
OCF growth 5YN/A